Showing datasets filtered by neurodegeneration.
- DepMap 24Q4 — Cancer Cell Line Dependency Mapds-c7bd27cb7ae8
Genome-wide CRISPR knockouts (Chronos) across 1,100+ cancer cell lines plus drug sensitivity panels — foundational resource for target validation.
- UK Biobank — Population Cohort with Genomics + Imagingds-e1f8489220a7
500K participants with genome-wide genotyping, neuroimaging (~50K), biofluid biomarkers, and longitudinal clinical outcomes — primary cohort for late-onset disease genetics.
- DepMap 24Q4 — Cancer Cell Line Dependency Mapds-231abeccbbe1
Genome-wide CRISPR knockouts (Chronos) across 1,100+ cancer cell lines plus drug sensitivity panels — foundational resource for target validation.
- UK Biobank — Population Cohort with Genomics + Imagingds-c92688f7513c
500K participants with genome-wide genotyping, neuroimaging (~50K), biofluid biomarkers, and longitudinal clinical outcomes — primary cohort for late-onset disease genetics.
- DepMap 24Q4 — Cancer Cell Line Dependency Mapds-e5ef08661f3f
Genome-wide CRISPR knockouts (Chronos) across 1,100+ cancer cell lines plus drug sensitivity panels — foundational resource for target validation.
- UK Biobank — Population Cohort with Genomics + Imagingds-4e0c757cdcd8
500K participants with genome-wide genotyping, neuroimaging (~50K), biofluid biomarkers, and longitudinal clinical outcomes — primary cohort for late-onset disease genetics.